Research programme: gene therapies - Genethon/Selecta Biosciences

Drug Profile

Research programme: gene therapies - Genethon/Selecta Biosciences

Latest Information Update: 12 Aug 2016

Price : $50

At a glance

  • Originator Genethon; Selecta Biosciences
  • Class Gene therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inborn urea cycle disorders; Methylmalonic acidaemia
  • Research Liver disorders; Muscular dystrophies

Most Recent Events

  • 09 Aug 2016 Preclinical trials in Inborn urea cycle disorders in USA (Parenteral)
  • 09 Aug 2016 Preclinical trials in Methylmalonic acidaemia in USA (Parenteral)
  • 13 May 2015 Early research in Muscular dystrophies and Liver disorders/Metabolic disorders (paediatric liver metabolic diseases) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top